Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous adipose-derived mesenchymal stem cell therapy - Hope Biosciences

Drug Profile

Autologous adipose-derived mesenchymal stem cell therapy - Hope Biosciences

Alternative Names: HB adMSCs; HB-adMSC

Latest Information Update: 20 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hope Biosciences
  • Developer Hope Biosciences; University of Texas Health Science Center at Houston
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II COVID 2019 infections
  • Phase I/II Alzheimer's disease; Rheumatoid arthritis; Traumatic brain injuries
  • Clinical Phase Unknown Cerebral palsy; Parkinson's disease; Spinal cord injuries; Thrombotic thrombocytopenic purpura
  • Preclinical Huntington's disease; Stroke

Most Recent Events

  • 12 Aug 2020 Hope Biosciences initiates an expanded access programme for HB adMSCs in amyotrophic lateral sclerosis (IV, Infusion) (NCT04514952)
  • 23 Apr 2020 Hope Biosciences plans a clinical trial for COVID-2019 infections in May 2020 (NCT04362189)
  • 22 Apr 2020 The US FDA approves third IND application for autologous adipose-derived mesenchymal stem cell therapy for a phase II trial in COVID-2019 infections
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top